News|Articles|April 2, 2026

FDA Action Update, March 2026: Lift on CRL, Expanded Approvals, and Priority Review

Catch up on any of the neurology headlines you may have missed in March 2026, compiled into 1 place by the NeurologyLive® team.

The FDA was busy in March 2026, making a number of decisions on potential new therapeutic agents, including lifting a complete response letter, accepting a new drug application for priority review, and granting expanded approvals.